Recent News
Signal Genetics Announces Publication of Meta-Analysis of its Colon Cancer Test-Previstage™ GCC Confirming Prognostic Capabilities in Patients with Colon Cancer.
New York, NY, January 23, 2012 – Signal Genetics, a privately held personalized medicine company focused on cancer, announced today the presentation of a paper entitled “Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis” at the 2012 American Society of Clinical Oncology Gastrointestinal Cancer Symposium held in San Francisco, CA January 21, 2012. The data from the paper demonstrate the value of implementing Previstage testing in patients with colorectal cancer to identify those patients at risk of relapse. (download pdf)
Signal Genetics Announces Launch of Next Generation Genetic Multiple Myeloma Predictive Testing Product – MyPRS Plus™
SAN DIEGO, CA, December 9, 2011–Signal Genetics announced today, at the American Society of Hematology Annual Meeting, that the Company is launching its next generation Multiple Myeloma product, MyPRS Plus™, effective January 1, 2012. Signal Genetics is a privately held predictive genetic testing company focused on oncology. In addition to providing the benefits of the earlier product, which effectively stratifies Multiple Myeloma patients between those at high vs. low risk for relapse and overall survival, MyPRS Plus™ provides additional insights in to the genetic characteristics of each individual patient and identifies the molecular sub-group to which each patient belongs. This classification is the most granular predictor of relapse and survival available for Myeloma patients. (download pdf)
Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstage™ GCC Colorectal Cancer Staging Test — Development of novel cancer tests also part of the collaboration
NEW YORK, (N.Y., USA); QUEBEC CITY (QUE. CAN.), June 29, 2011– Signal Genetics, a privately held predictive genetic testing company focusing on oncology, and DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes high-value cancer diagnostic tests, today announced a collaboration arrangement valued at US$13.3M over the first five years. This collaboration aims to maximize the commercialization of Previstage™ GCC Colorectal Cancer Staging Test, and further develop novel genomic cancer tests in the field of Personalized Medicine. (download pdf)
NeoGenomics Inks Distribution Deal for Signal Genetics' Multiple Myeloma Gene Expression Test
New York, NY – May 26, 2011 (GenomeWeb News) – NeoGenomics Laboratories will offer Signal Genetics' new gene expression profile test for multiple myeloma to pathologists and hospital-based hematologists and oncologists nationwide under a deal announced today.
Under the terms of the agreement, Signal Genetics' Myeloma Prognostic Risk Signature test will be performed at its CLIA-certified laboratory in Little Rock, Ark., and results will be incorporated into NeoGenomics' test reports to be provided to its customers along with other ancillary diagnostic tests, Signal Genetics said. (download pdf)
Effective March 4, 2011, Medicare approved coverage for MyPRS™ for Medicare beneficiaries.
Click here for details regarding the coverage policy.
Plethora of New Products to be Showcased at 2011 Molecular Medicine Tri-Conference
Needham, MA – February 7, 2011 – Cambridge Healthtech Institute announces 43 exhibitors to showcase new products at the 18th Molecular Medicine Tri-Conference, taking place February 23-25, at the Moscone Convention Center, San Francisco, CA. The Molecular Medicine Tri-Conference is the predominant event on the west coast focused on integrating the entire spectrum of drug development. (download pdf)
Caris will offer Signal’s Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test
New York, NY and Irving, Texas, January 10, 2011 – Caris will offer Signal’s Myeloma Prognostic Risk Signature (MyPRS) gene expression profile test to community-based hematologists and medical oncologists in the U.S. MyPRS analyzes and applies an algorithm to a defined number of relevant genes to determine the gene expression profile associated with the patient’s condition. (download pdf)
Signal clinches maiden deal for gene profiling cancer test with Caris
By Tina Tan, Clinica, January 7, 2011 – Signal Genetics has enlisted Caris Life Sciences to sell its new gene expression profile test in the US. The test is used in patients with multiple myeloma, a cancer of the white blood cells. This is the first commercial deal for Signal's MyPRS (myeloma prognostic risk signature) test since it was launched last month at the annual meeting of the American Society of Hematology, held in Orlando, Florida. Previously, the product was available only on a research basis, said Greg Richard, Signal's executive vice-president of commercial operations. (download pdf)
Signal Genetics and Caris Life Sciences Announce Commercialization Partnership for New Myeloma Gene Expression Test
New York, NY and Irving, Texas, January 5, 2011 – Signal Genetics, the parent company of Myeloma Health LLC, a privately held predictive genetic testing company focused on oncology, and Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, today announced a new agreement under which Caris Life Sciences will offer Signal Genetics’ new gene expression profile test for Multiple Myeloma (MyPRS™) to community-based hematologists/medical oncologists nationwide. (download pdf)
Signal Genetics Announces Launch of Revolutionary Molecular Test for Multiple Myeloma Patients
New York, NY, December 1, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the launch of their revolutionary molecular test for individuals diagnosed with multiple myeloma, MyPRS™. (download pdf)
Signal Genetics Announces Establishment of Scientific Advisory Board
New York, NY, October 26, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the formation of their Scientific Advisory Board. (download pdf)
Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
New York, NY, September 22, 2010 – Signal Genetics, the parent company of Myeloma Health, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies’ goals of markers for patient selection helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells. (download pdf)
Signal Genetics Announces Licensing Agreement of Novel Microarray Diagnostic for the Predictive Determination of Multiple Myeloma Staging & Prognosis with University of Arkansas Medical Sciences
New York, NY, September 7, 2010 – Signal Genetics, a privately held predictive genetic testing company directed toward cancer patients, today announced that the company has acquired an exclusive license to technologies developed at the University of Arkansas Medical Sciences. (download pdf)